Clinical application of lobaplatin combined with docetaxel in adjuvant chemotherapy for triple-negative breast cancer in elderly patients

Weihua Jiang, Li Wang, Yongtao Li, Chenguang Zhang, Lina Yi, Jianghua Ou



Abstract: Objective: To investigate the adverse reactions and efficacy of docetaxel combined with lobaplatin in adjuvant chemotherapy for triple-negative breast cancer in elderly patients. Methods: A total of 96 elderly triple-negative breast cancer patients admitted to our hospital from January 2008 to December 2011 were randomly divided into two groups. A group of 56 patients received docetaxel 75 mg·m-2, intravenous drip, d1; lobaplatin 30 mg·m-2,intravenous drip, d1; 21 days repeat, a total of 6 cycles. A group of 40 patients received chemotherapy for 6 cycles with an anthracycline-containing (TEC) regimen. Comparison of adverse reactions and 5-year disease-free survival in both groups. Results: The incidence of thrombocytopenia was significantly higher in 56 patients with TL regimen than those with TCE-containing anthracyclines (P=0.005). But the incidence of cardiotoxicity was 32.5% in the TEC group. And the difference was statistically significant (P=0.008). The 5-year disease-free survival rate was 73.2% in the TL group and 67.5% in the TEC group. There was no statistical difference. Conclusion: Docetaxel combined with lobaplatin in the treatment of elderly triple-negative breast cancer has no significant difference in efficacy compared with traditional anthracycline-containing drugs, but it can avoid the cardiotoxicity caused by anthracyclines. It’s a new option for elderly TNBC adjuvant chemotherapy, suggesting to expand the sample content for further research. 


Docetaxel; Lobaplatin; Triple-negative breast cancer

Full Text:



Austin D, Hamilton N, Elshimali, et al. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment [J]. Oncotarget, 2018, 9 (74): 33912-33930. doi: 10.18632/oncotarget.26089.

Bergen ES, Bartsch R. My burning issues in the neoadjuvant treatment for breast cancer [J]. Memo, 2018, 11(1): 27-30. doi: 10.1007/s12254-017-0378-5.

Jung Y, Lee SJ, Lee J, et al. Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment [J]. Breast Cancer, 2018, 21(2): 182-189. doi: 10.4048/jbc.2018.21.2.182.

Downey LB. Adjuvant treatment of breast cancer in the elderly. Understanding and addressing the challenges [J]. Oncology, 2008, 22(3): 286-293. doi:

Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation [J]. N Engl J Med, 2017, 377(6): 523-533. doi: 10.1056/NEJMoa1706450.

Lee JM, Hays JL, Chiou VL, et al. Phase Ⅰ/Ⅰb study of olaparib and carboplatin in women with triple negative breast cancer [J]. Oncotarget, 2017, 8(45): 79175-79187. doi: 10.18632/oncotarget.16577.

Kummar S, Wade JL, Oza AM, et al. Randomized phase Ⅱ trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent,advanced triplenegative breast cancer [J]. Invest New Drugs, 2016, 34(3): 355-363. doi: 10.1007/s10637-016-0335-x.

Agrawal LS, Mayer IA. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice? [J]. Clin Adv Hematol Oncol, 2014,12(10): 654-658.

Domagala P, Hybiak J, Rys J, et al. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers [J]. Oncotarget, 2016, 7(42): 68662-68673. doi: 10.18632/oncotarget.11900.

Valsecchi ME, Kimmey G, Bir A, et al. Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer [J]. Rev Recent Clin Trials, 2015, 10(2): 101-110.

Fan Y, Xu BH, Yuan P, et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer [J]. Ann Oncol, 2013, 24 (5): 1219-1225. doi: 10.1093/annonc/mds603.

Zhang J, Lin Y, Sun XJ, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer [J]. Ann Oncol, 2018, 29(8): 1741-1747. doi: 10.1093/annonc/mdy209.

Xie CY, Xu YP, Jin W, et al. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer [J]. Anticancer Drugs, 2012, 23(7): 698-705. doi: 10.1097/CAD.0b013e328352cc10.

Hu Xichun, Zhang Jian, Chen Dedian, et al. Chinese expert consensus on anthracyclines in the treatment of breast cancer [J]. Chinese Cancer Clinic, 2018, 45(3): 120-125. Doi: 10.3969/ J.issn.1000-8179.2018.03.198.

Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention [J]. Heart, 2018, 104(12): 971-977. doi: 10.1136/heartjnl-2017-312103.

Janbabai G, Nabati M, Faghihinia M, et al. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy [J]. Cardiovasc Toxicol, 2017, 17(2): 130-139. doi: 10.1007/s12012-016-9365-z.

Han Ying, LI Qing, Xu Binghe, et al. Clinical study on the safety and tolerance of anthracycline adjuvant chemotherapy in elderly breast cancer patients [J]. Chin J Cancer, 2014, 24(5): 367-373. Doi: 10.3969/ J.issn.1007-3969.2014.05.008.

Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treater with adjuvant anthracycline chemotherapy for breast cancer [J]. J Clin Oncol, 2007, 25(25): 3808-3815. doi: 10.1200/JCO.2006.10.4976.



  • There are currently no refbacks.

Copyright (c) 2020 蒋 威华, 王 黎, 李 涌涛, 张 晨光, 伊 丽娜, 欧 江华

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.